• About
    • Viatris in Europe
      • Unlocking European patients access to medicines
    • Viatris' Manufacturing Footprint
    • Sustainability at Viatris
    • Memberships and Partnerships
  • Policy
    • Policy for Access
      • Preserving Patients Access to Off-Patent Medicines
      • Protecting Access to Essential Antibiotics
      • VAM: Improving Patient Outcomes with Existing Medicines
      • Securing Access to Critical Medicines
    • Green Deal
      • Environmental Stewardship
    • Strategic Autonomy & Industrial Strategy
      • Investing in Supply Resilience to Secure Access
      • Best Procurement Practices
    • Digital Strategy
      • European Health Data Space
  • Public Health
    • AMR
    • Tackling Noncommunicable Diseases
    • Advancing Access to Anaphylaxis Treatment
    • Influenza
    • Infectious Diseases
    • COVID-19
  • Conversation
Show Menu

Collaborative solutions for Antimicrobial Resistance

Strategic policy actions through which we can build sustainable markets for antibiotics and safeguard global health.

Antimicrobial resistance (AMR) is the result of microorganisms such as bacteria, viruses, parasites, and fungi becoming resistant to antimicrobials like antibiotics, designed to kill or inhibit their growth₁. AMR is recognized around the world as a significant threat to global health and economic development, and a major driver of death potentially accounting for more deaths than HIV/AIDS and malaria worldwide₂.

By 2050, it is estimated that AMR will be responsible for up to 10 million deaths annually₃, will cause more deaths than cancer unless concerted efforts are undertaken to counter its progression, and result in $1 trillion in additional healthcare costs₃.

As the progression of AMR can render antibiotics less effective, common infections, such as wound infections, urinary tract infections, c-sections and pneumonia will increasingly be associated with severe complications and increased risk of death.

Insights from PLATINEA in Sweden:

PLATINEA (PLATform for INnovation of Existing Antibiotics) collaboration platform in Sweden is a best practice and scalable model across Europe and globally for stakeholder collaboration to fight antimicrobial resistance4. PLATINEA is working to promote more effective antibiotic use in clinics, as well as to maintain supply security through helping health authorities build more sustainable market conditions for antibiotics.

As part of PLATINEA, Viatris’ work is aligned with our global work to fight AMR and underpins our deep commitment to advance access to medicines. In a new film produced for us by BBC StoryWorks Commercial Productions, we shine light on PLATINEA as model to promote more effective antibiotic use in clinics, as well as to maintain supply security through helping health authorities build more sustainable market conditions for antibiotics.

Learn More

Policy Recommendations

Actionable solutions are needed to stabilize the market and safeguard access to mature antibiotics, and every step strengthens our collective ability to combat AMR and advance access to life-saving antibiotics. See full recommendations here
  1. United Nations Environment Program, Bracing for Superbugs: Strengthening environmental action in the One Health response to antimicrobial resistance, 2023
  2. The Lancet, Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
  3. The World Health Organization Antimicrobial Factsheet, 2023

Leaving the Viatris site

You are now leaving the Viatris page for a Viatris affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Viatris affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Continue
Cancel

Viatris Policy and Government Affairs

  • Privacy Notice
  • Cookie Notice
  • Terms of Use
  • Contact Us
  • Privacy Notice
    • Dutch
    • French
  • Cookie Notice
    • Dutch
    • French
  • Terms of Use
  • Contact Us
© 2025 Viatris
Created on: 6/25/2021
Updated on: 2/7/2024